QingSong Health Corporation
轻 松 健 康 集 团
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2661)

VOLUNTARY ANNOUNCEMENT
INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This is a voluntary announcement made by QingSong Health Corporation (the "**Company**") to provide its shareholders and potential investors with information in relation to the latest developments regarding the Company.

Reference is made to the circular of the Company dated April 30, 2026 and the announcement of the Company dated May 22, 2026, pursuant to which, among others, the board (the "**Board**") of directors (the "**Directors**") of the Company may conduct repurchases by exercising its powers under the repurchase mandate given or to be given to the Board pursuant to the resolutions of each year to repurchase shares of the Company (the "**Shares**") not exceeding 10% of the total number of the issued Shares as at the date of such annual general meeting, being up to 20,637,420 Shares based on the total number of issued Shares as at May 22, 2026, with each mandate to expire upon the conclusion of the next annual general meeting of the Company.

The Board wishes to announce that on June 22, 2026, the Board has resolved to exercise the share repurchase mandate, under which the Company may repurchase up to HK$100 million in value of its outstanding Shares from the open market from the date of this announcement until the conclusion of the annual general meeting to be held. The Company expects to fund repurchases under the share repurchase mandate from surplus cash on its balance sheet.

The Company's proposed repurchases under the share repurchase mandate may be made from time to time on the open market at prevailing market prices, depending on market conditions and in accordance with applicable rules and regulations and its insider trading policy. Under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), the repurchase price of each Share shall not be higher by 5% or more than the average closing market price of the Shares over the five trading days immediately preceding each repurchase.

The Company will repurchase under the authority of the repurchase mandate granted by the Shareholders passed on May 22, 2026. The Shares repurchased under the share repurchase mandate will be held as treasury Shares for the purpose of the 2026 Share Incentive Scheme adopted by the Company.

The Company will conduct the proposed share repurchase in compliance with the memorandum and articles of association of the Company, the Listing Rules, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Law of the Cayman Islands and all applicable laws and regulations to which the Company is subject to.

The Board believes that a share repurchase in the present conditions will demonstrate the Company's confidence in its business outlook and prospects and would benefit the Company and create value to the Shareholders ultimately.

The Board believes that the current financial resources of the Company would enable it to implement the share repurchase without causing any material impact on its working capital.

The Board will review the share repurchase mandate periodically, and may authorize adjustment of its terms and size.

Shareholders and potential investors should note that the implementation of the on-market share repurchase by the Company will be subject to prevailing market conditions and will be at the absolute discretion of the Board and/or its authorized person(s). There is no assurance of the timing, quantity or price of any repurchase or whether the Company will make any repurchase at all. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
QingSong Health Corporation
轻松健康集团
YANG Yin
Chairlady of the Board, Executive Director and Chief Executive Officer

Hong Kong, June 22, 2026

As of the date of this announcement, the Board of the Company comprises: (i) Ms. YANG Yin as executive director; (ii) Mr. ZHAO Yuping, Mr. ZHENG Kaihuan and Mr. WU Bin as non-executive directors; and (iii) Dr. WANG Xiaoyan, Mr. CHOW Yiu Ming and Ms. JI Wenting as independent non-executive directors.